Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2015

View Archived Issues

Inotek Pharmaceuticals begin dosing in pivotal phase III study of trabodenoson

OMT and Armo BioSciences enter into anti-PD-1 antibody agreement

Kolltan Pharmaceuticals reports efficacy data from phase Ib KTN-3379 trial

New phase IIa study investigates simeprevir, odalasvir and AL-335 treatment regimen in HCV

First clinical results presented for novel radiotracer [123/131I]IMAZA

[111In]CP04 could represent a step forward in medullary thyroid carcinoma imaging

Arisaph starts phase II trial of niacin analogue ARI-3037-MO in patients with NAFLD or NASH

HKU and international research teams identify novel PARP-1 complex

DSMB recommends continuation of phase III study of Vyxeos for AML

Luc Therapeutics licenses NMDA modulators for depression to Novartis

Fecal microbiome transplant shows favorable safety profile in HIV-infected subjects

FDA grants orphan drug designation to receptor-Fc fusion protein for the treatment of ovarian cancer

Responses seen with avelumab in trials in mesothelioma, gastric/gastroesophageal junction cancer

Novel NNT gene mutation linked to left ventricular noncompaction

First-in-human results reveal activity of SYD-985 in patients with solid tumors

Curis expands cancer drug pipeline

FDA grants orphan drug designation and fast track status to resunab for cystic fibrosis

FDA approves Coagadex for hereditary factor X deficiency

Tris Pharma's Dyanavel XR approved in U.S. for ADHD in children

Synta terminates phase III trial of ganetespib in NSCLC

InterMune discloses antifibrotic pyridinones

Taisho Pharmaceutical patents orexin receptor antagonists

Sumitomo Dainippon Pharma describes alpha7 nAChR positive allosteric modulators

Eicosis develops soluble epoxide hydrolase inhibitors

Medshine Discovery reports hedgehog signaling pathway inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...